Key result
Aliskiren improves blood pressure control, renoprotection, and cardiovascular disease prevention in patients with CKD.
Why the study?
The renin-angiotensin-aldosterone system plays pivotal roles in CKD progression and its complications, and aliskiren may be effective for management but requires review.
Does aliskiren improve the management of chronic kidney disease and its complications?
Does aliskiren improve the management of chronic kidney disease and its complications?
This review discusses the potential role of the direct renin inhibitor aliskiren in managing chronic kidney disease and its cardiovascular complications.
May support aliskiren in CKD management; leaves open routine adoption pending randomized trials.
The renin-angiotensin-aldosterone system (RAAS) plays pivotal roles in the pathogenesis of chronic kidney disease (CKD) progression and its increased complications such as hypertension (HT) and cardiovascular diseases (CVD). Previous studies suggested that aliskiren a direct renin inhibitor, blocks RAAS and may be effective for the management of CKD and its complications. This review focuses on the effects of aliskiren on CKD.
No takes yet. Share an insight, caveat, or question.
Morishita et al. (2012) conducted a review in Chronic Kidney Disease. Aliskiren was evaluated. Aliskiren provides beneficial effects for renoprotection, blood pressure control, and the prevention of cardiovascular disease in patients with chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: